HC Wainwright Expects Reduced Earnings for Maze Therapeutics

Maze Therapeutics, Inc. (NASDAQ:MAZE – Free Report) – Investment analysts at HC Wainwright cut their FY2026 earnings per share estimates for shares of Maze Therapeutics in a research note issued on Tuesday, November 10th. HC Wainwright analyst A. Ghosh now expects that the company will earn ($2.86) per share for the year, down from their prior estimate of ($2.63). HC Wainwright currently has a “Buy” rating and a $110.00 target price on the stock. The consensus estimate for Maze Therapeutics’ current full-year earnings is ($2.76) per share. HC Wainwright also issued estimates for Maze Therapeutics’ Q4 2026 earnings at ($0.83) EPS, Q1 2027 earnings at ($0.80) EPS, Q2 2027 earnings at ($0.81) EPS, Q3 2027 earnings at ($0.82) EPS, Q4 2027 earnings at ($0.72) EPS, FY2027 earnings at ($3.15) EPS, FY2028 earnings at ($2.55) EPS, FY2029 earnings at ($2.39) EPS and FY2030 earnings at ($2.52) EPS.

Several other research firms have also commented on MAZE. BTIG Research reissued a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a report on Tuesday, September 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a report on Monday, September 21st. TD Cowen raised shares of Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. JPMorgan Chase & Co. reduced their price target on shares of Maze Therapeutics from $53.00 to $51.00 and set an “overweight” rating on the stock in a research report on Wednesday. Finally, Wedbush lifted their price objective on shares of Maze Therapeutics from $48.00 to $49.00 and gave the company an “outperform” rating in a research note on Tuesday. Three equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Maze Therapeutics presently has an average rating of “Buy” and a consensus price target of $65.50.

Check Out Our Latest Research Report on MAZE

Maze Therapeutics Trading Down 4.9%

MAZE opened at $34.33 on Thursday. Maze Therapeutics has a twelve month low of $21.95 and a twelve month high of $53.65. The company has a 50-day simple moving average of $28.68 and a 200 day simple moving average of $31.54. The company has a quick ratio of 18.31, a current ratio of 14.14 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $1.88 billion, a price-to-earnings ratio of -12.95 and a beta of 2.04.

Maze Therapeutics (NASDAQ:MAZE – Get Free Report) last issued its quarterly earnings results on Monday, November 9th. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.01).

Hedge Funds Weigh In On Maze Therapeutics

A number of institutional investors have recently added to or reduced their stakes in MAZE. TRV GP IV LLC bought a new position in shares of Maze Therapeutics in the 2nd quarter valued at $133,502,907. ARCH Venture Management LLC acquired a new stake in shares of Maze Therapeutics during the 2nd quarter valued at $122,983,582. BlackRock Inc. acquired a new stake in shares of Maze Therapeutics during the 2nd quarter valued at $104,525,000. Jupiter Topco LLC acquired a new stake in shares of Maze Therapeutics during the 2nd quarter valued at $101,764,000. Finally, Alphabet Inc. bought a new stake in Maze Therapeutics during the 2nd quarter worth $41,435,000.

Insider Transactions at Maze Therapeutics

In related news, CEO Jason V. Coloma sold 34,501 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $26.29, for a total value of $907,031.29. Following the sale, the chief executive officer directly owned 18,151 shares of the company’s stock, valued at $477,189.79. This trade represents a 65.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 16,141 shares of Maze Therapeutics stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $26.36, for a total value of $425,476.76. Following the completion of the transaction, the chief marketing officer owned 16,141 shares in the company, valued at approximately $425,476.76. This represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 176,849 shares of company stock valued at $4,741,878. Corporate insiders own 5.30% of the company’s stock.

Latest Maze Therapeutics News

These are some of the MAZE news items that stood out recently:

Maze Therapeutics Company Profile

(Get Free Report)

Maze Therapeutics is a clinical-stage biotechnology company developing precision medicines for people with serious diseases. Its research uses human genetics and functional genomics to identify disease-related biological pathways and potential drug targets. The company’s Maze Compass platform is designed to connect genetic insights with biological research to guide drug discovery and development. Its investigational programs have included approaches for APOL1-mediated kidney disease and Pompe disease; these are not marketed treatments.

Recommended Stories

Earnings History and Estimates for Maze Therapeutics (NASDAQ:MAZE)

Receive News & Ratings for Maze Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maze Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.